CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)
Beginning balance (in shares) at Jun. 30, 2024		2,279,948
Beginning balance at Jun. 30, 2024	$ 56,787	$ 114	$ 69,660	$ 8,584	$ (21,571)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	7,042				7,042
Foreign currency translation	(411)			(411)
Stock-based compensation	1,048		1,048
Net restricted stock activity (in shares)		15,481
Net restricted stock activity	(74)	$ 1	(75)
Common stock issued in connection with Alline acquisition (Note 13) (in shares)		140,552
Common stock issued in connection with Alline acquisition (Note 13)	3,000	$ 7	2,993
Stock warrants issued in connection with debt	1,252		1,252
Ending balance (in shares) at Mar. 31, 2025		2,435,981
Ending balance at Mar. 31, 2025	68,644	$ 122	74,878	8,173	(14,529)
Beginning balance (in shares) at Dec. 31, 2024		2,435,981
Beginning balance at Dec. 31, 2024	66,718	$ 122	73,243	8,132	(14,779)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	250				250
Foreign currency translation	41			41
Stock-based compensation	383		383
Stock warrants issued in connection with debt	1,252		1,252
Ending balance (in shares) at Mar. 31, 2025		2,435,981
Ending balance at Mar. 31, 2025	$ 68,644	$ 122	74,878	8,173	(14,529)
Beginning balance (in shares) at Jun. 30, 2025	2,435,981	2,435,981
Beginning balance at Jun. 30, 2025	$ 185,616	$ 122	75,243	8,286	101,965
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,547				2,547
Foreign currency translation	(304)			(304)
Exercise of stock options (in shares)		24,564
Exercise of stock options	607	$ 1	606
Stock-based compensation	844		844
Net restricted stock activity (in shares)		25,666
Net restricted stock activity	(159)	$ 1	(160)
Common stock issued in connection with Alline acquisition (Note 13)	0
Common stock issued in connection with warrant exercise (in shares)		12,567
Common stock issued in connection with warrant exercise	$ 299	$ 1	298
Ending balance (in shares) at Mar. 31, 2026	2,498,778	2,498,778
Ending balance at Mar. 31, 2026	$ 189,450	$ 125	76,831	7,982	104,512
Beginning balance (in shares) at Dec. 31, 2025		2,498,778
Beginning balance at Dec. 31, 2025	188,708	$ 125	76,591	8,215	103,777
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	735				735
Foreign currency translation	(233)			(233)
Stock-based compensation	$ 240		240
Ending balance (in shares) at Mar. 31, 2026	2,498,778	2,498,778
Ending balance at Mar. 31, 2026	$ 189,450	$ 125	$ 76,831	$ 7,982	$ 104,512